This company develops FDA-cleared, AI-driven software solutions for quantitative analysis of brain MRI scans in neurology. Their platform assists radiologists and neurologists by comparing and quantifying longitudinal imaging data to support data-driven clinical decision-making. The technology aims to improve the speed, consistency, and accuracy of monitoring neurological conditions like Multiple Sclerosis.
Funding
Funding not disclosed
MJFounders
Product
Problem
Neurologists and radiologists must interpret complex brain MRI scans to detect subtle disease activity and monitor progression, but manual analysis is time‑consuming, subject to inter‑reader variability, and often lacks quantitative rigor. This hampers early diagnosis, treatment decisions, and consistent reporting across neurological disorders.
Solution
icometrix delivers FDA‑cleared, CE‑marked AI software—branded icobrain—that automatically extracts quantitative biomarkers from brain MRI and presents them in structured, longitudinal reports. The platform supports disease‑specific workflows for multiple sclerosis, dementia, amyloid‑related imaging abnormalities, stroke, traumatic brain injury, epilepsy, Parkinson’s disease, and brain tumors. By integrating directly with PACS, EMR, and HL7 interfaces, the solution fits into existing clinical pipelines, reducing reading time, improving detection of disease activity, and enabling data‑driven therapeutic monitoring. Clinicians receive reproducible metrics, visual overlays, and AI‑generated insights that support precise diagnosis, treatment eligibility assessment, and ongoing patient management.
Target Audience
Primary users are radiology and neurology departments in hospitals, academic medical centers, and specialty clinics that manage multiple sclerosis, dementia/Alzheimer’s disease, stroke, traumatic brain injury, epilepsy, Parkinson’s disease, or brain tumors. The platform also serves pharmaceutical sponsors conducting neurology clinical trials.
Features
- FDA‑cleared deep‑learning algorithms for lesion detection, brain‑volume quantification, white‑matter hyperintensity grading, and ARIA (edema and microhemorrhage) assessment.
- Disease‑tailored modules (icobrain MS, icobrain dm, icobrain aria, etc.) that provide condition‑specific biomarkers and progression scores.
- Automated longitudinal comparison of serial MRIs with statistical mapping against age‑matched normative databases.
- Structured output formats: DICOM overlays for PACS, HL7‑ready reports for EMR/EHR, and pre‑filled radiology templates.
- Cloud‑hosted analytics pipeline with secure, HIPAA‑compliant data storage and role‑based access controls.
- Validated clinical performance: 150 % increase in MS disease‑activity detection, 40 % faster radiology reads, and 2.5× quicker identification of treatment failure.
- Integrated CPT‑III® billing codes (0865T/0866T) and support for insurer claim processing across U.S. regions.
- Scalable deployment on any MRI vendor platform, including seamless integration with GE HealthCare’s AIR x™ Brain suite.